Imperial College London
Ben Creagh-Brown

Ben Creagh-Brown

Faculty of Medicine, National Heart & Lung Institute

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

b.creagh-brown08

 
 
//

Location

 

Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{RECOVERY:2022:10.1016/S0140-6736(22)00163-5,
author = {RECOVERY, Collaborative Group},
doi = {10.1016/S0140-6736(22)00163-5},
journal = {The Lancet},
pages = {665--676},
title = {Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
url = {http://dx.doi.org/10.1016/S0140-6736(22)00163-5},
volume = {399},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. METHODS: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (2
AU  - RECOVERY,Collaborative Group
DO  - 10.1016/S0140-6736(22)00163-5
EP  - 676
PY  - 2022///
SN  - 0140-6736
SP  - 665
TI  - Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(22)00163-5
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35151397
UR  - http://hdl.handle.net/10044/1/95149
VL  - 399
ER  -
Download